Amyloid-beta precursor protein–Tau protein-protein interface (APP–Tau PPI)

The Amyloid-beta precursor protein (APP)–Tau protein-protein interface represents a critical pathological link in the development of Alzheimer's disease and other tauopathies. APP and Tau are the primary proteins associated with the hallmark extracellular plaques and intracellular tangles of the disease, and their direct physical interaction is thought to be a precursor event that facilitates the transition from soluble protein states to toxic aggregates. Under physiological conditions, these proteins independently contribute to essential processes such as axonal transport, synaptic maintenance, and microtubule stability; however, their pathological binding can promote the formation of neurotoxic amyloid-beta subtypes and accelerate tau hyperphosphorylation. Therapeutic strategies targeting this interface aim to disrupt the physical association between APP and Tau using specialized inhibitors, such as synthetic peptides like the APP1-Tau1 mixture or linked "Flex" peptides. Preclinical studies in animal models have demonstrated that blocking this interaction can significantly reduce amyloid plaque burden and rescue cognitive functions. While no drugs targeting this specific interface are currently FDA-approved, the development of peptide-based modulators and small molecules remains an active area of neurodegeneration research. Key challenges for this target include ensuring effective drug delivery across the blood-brain barrier and avoiding the disruption of the essential homeostatic functions these proteins perform in healthy neurons.

Other names

APP-Tau interactionAmyloid precursor protein-Tau complexAPP-Tau bindingAPP-Tau PPI

Inhibition of the protein-protein interaction (PPI) between Amyloid-beta precursor protein (APP) and Tau protein to prevent pathological aggregation, reduce amyloid plaque burden, and ameliorate cognitive decline.